%0 Journal Article %A Luis Eduardo R. Cunha %A Adilson A. Stolet %A Marcelo A. Strauch %A Victor A. R. Pereira %A Carlos H. Dumard %A Patrícia N. C. Souza %A Juliana G. Fonseca %A Francisco E. Pontes %A Leonardo G. R. Meirelles %A José W. M. Albuquerque %A Carolina Q. Sacramento %A Natalia Fintelman-Rodrigues %A Tulio M. Lima %A Renata G. F. Alvim %A Russolina B. Zingali %A Guilherme A. P. Oliveira %A Thiago M. L. Souza %A Amilcar Tanuri %A Andre M. O. Gomes %A Andréa C. Oliveira %A Herbert L. M. Guedes %A Leda R. Castilho %A Jerson L. Silva %T Equine hyperimmune globulin raised against the SARS-CoV-2 spike glycoprotein has extremely high neutralizing titers %D 2020 %R 10.1101/2020.08.17.254375 %J bioRxiv %P 2020.08.17.254375 %X COVID-19 pandemic caused approximately 750,000 deaths and over 20 million confirmed cases of infection by SARS-CoV-2 within 8 months since the emergence of the virus. While there are no vaccines approved and considering the difficulty in meeting the large vaccination demand worldwide, the potential use of passive immunization should be considered based on existing successful therapies against many diseases. Here we demonstrate that hyperimmune globulin preparations raised in horses against the recombinant trimeric spike (S) glycoprotein of SARS-CoV-2 in the prefusion conformation provide very high ELISA titers as well as highly potent neutralizing activity against SARS-CoV-2. Five horses were subcutaneously inoculated for 6 weeks with the recombinant S protein (ectodomain, residues 1-1208). Four out of the 5 horses presented a strong immune response. Considering the average of all 5 horses, ELISA titers above 1:1,000,000 and neutralizing titers (PRNT90) reaching 1:14,604 were observed. When compared with the plasma of three convalescent COVID-19 patients, sera of immunized horses displayed approximately 140-fold higher neutralizing titers measured as PRNT90. To prevent eventual side effects caused by horse antiserum, IgG was digested with pepsin and purified by fractional salt precipitation to eliminate Fc fragments, a process that is industrially used for the production of passive immunization F(ab’)2 concentrates against rabies, tetanus and snake venoms. The high neutralizing titers against SARS-CoV-2 obtained for the unprocessed sera were confirmed for the F(ab’)2 fragments and were 150-fold higher than the PRNT90 neutralizing titers of plasma of three COVID-19 convalescent patients. The great advantage of using the recombinant trimeric S glycoprotein is that it is safe and provides quick adaptive immunity in horses. Our data show the perspective of using hyperimmune anti-SARS-CoV-2 F(ab’)2 preparations as a passive immunization therapy in humans, similar to therapies that have been safely used for decades against rabies, tetanus and snake venoms.Competing Interest StatementThe authors have declared no competing interest. %U https://www.biorxiv.org/content/biorxiv/early/2020/08/21/2020.08.17.254375.full.pdf